Neal F. Kassell, MD, the Founder and Chairman of the Focused Ultrasound Foundation, recently sat down (virtually) with Chase Koch, the President of Koch Disruptive Technologies, for an in-depth discussion about the field of focused ultrasound and how their organizations are working together to revolutionize therapy with this highly disruptive technology.
On July 9, 2020, we launched a podcast and the first in a three-part blog series that was edited and condensed from their conversation. The blog discusses KDT and Koch Industries, why they are excited about focused ultrasound, and their message to the community at large.
Listen: “FUS Foundation and Koch Disruptive Technologies Discuss Advancing Focused Ultrasound”
The second article in the series (in two weeks) will explore the state of the field as it transitions from research to commercialization, and KDT’s relationship with the Foundation as they pursue their shared goal of improving the lives of millions around the world with focused ultrasound in the shortest time possible.
And in the final installment to be shared in August, Dr. Kassell and Mr. Koch will discuss KDT’s current position in the field, future investment plans, and how they feel about spawning the first focused ultrasound “unicorn” (a privately held company with a valuation of more than one billion dollars) via Israeli manufacturer Insightec.
The page will be updated with the blog links as they become available. To receive them directly, please subscribe to the Foundation's biweekly e-newsletter.
Focused Ultrasound Foundation and Koch Disruptive Technologies Discuss Advancing Focused Ultrasound
Chase Koch, President, Koch Disruptive Technologies
Neal F. Kassell, MD, Founder and Chairman, Focused Ultrasound Foundation
Read the full transcript >
The Foundation established a dedicated Cancer Immunotherapy Program in 2015, with a mission to explore the potential of focused ultrasound in the cancer immunotherapy field. As part of this program, the Foundation invites funding applications for collaborative projects that address key questions driving the field.
New and ongoing clinical and preclinical research is examining the use of focused ultrasound in initiating an anti-tumor immune response – either alone or in combination with immunotherapies – to treat cancer.